Healthcare Stocks on ASX Today: Clinuvel Pharmaceuticals, Healius and Avita Medical Inc Shares Move Across the Sector

Sonal Goyal

06 November 2026 06:09 PM AEDT

Healthcare Stocks on ASX Today: Clinuvel Pharmaceuticals, Healius and Avita Medical Inc Shares Move Across the Sector

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Clinuvel Pharmaceuticals Ltd (CUV) traded at A$7.52 (-2.84%) during the 6 November 2026 session.
Healius Ltd (HLS) traded at A$0.50 (+1.01%) and Avita Medical Inc (AVH) at A$4.55 (-1.73%).
The S&P/ASX 200 Health Care index eased 0.20% to 35,258.30 over the same session.

Company	Ticker	Price (A$)	% Change
Clinuvel Pharmaceuticals Ltd	CUV	A$7.52	-2.84%
Healius Ltd	HLS	A$0.50	+1.01%
Avita Medical Inc	AVH	A$4.55	-1.73%

Healthcare stocks are a diverse group, spanning medical devices, diagnostics, aged care, pharmaceuticals and biotechnology. This article brings together Clinuvel Pharmaceuticals Ltd, Healius Ltd, Avita Medical Inc, which share a sector label but have very different Business models. Each stock is paired below with its latest company release, shown with its own date, so readers can see the reported figures behind the session prices. The session was mixed. Eight of the 24 stocks in this series rose and 16 fell, with the largest declines in Mesoblast (-6.45%), Clarity (-6.56%) and 4DMedical (-5.39%). The S&P/ASX 200 Health Care Index eased 0.20% to 35,258.30, while the S&P/ASX 200 was down 0.49% at 9,020.80 and the All Ordinaries rose 0.66% to 9,144.70.

Clinuvel Pharmaceuticals Ltd (ASX:CUV)

Clinuvel traded at A$7.52, down 2.84%. On 30 October 2026 it announced that it had filed a dossier for NEURACTHEL Instant, its second pharmaceutical product, with European regulators through the decentralised procedure. The review is expected to take 300 days plus clock stops, and the company said the first national reviews are in three EU countries.

Healius Ltd (ASX:HLS)

Healius traded at A$0.50, up 1.01%. Its 25 September 2026 announcement said it had agreed to sell Agilex Biolabs to Novotech at an Enterprise value of A$160 million, with completion expected in the second half of FY27 subject to conditions.

Avita Medical Inc (ASX:AVH)

Avita traded at A$4.55, down 1.73%. Its 18 August 2026 release reported positive PermeaDerm study results, with a 70% economic advantage over allograft based on product cost per percentage of body surface area treated, and comparable clinical outcomes. The company also reported a 96% reduction in preparation time.

Sector Context

These three stocks sit in the health care index, which eased 0.20% on the day, while the broader market was mixed. Session moves in this group ranged from small gains to declines of more than 5%, and the company releases in the pack cover reporting periods from August to late October 2026. Because the releases are dated separately from the session, they describe reported results and events rather than explaining the price moves.

FAQs

Q: What did CUV, HLS and AVH trade at on 6 November 2026?

A: Clinuvel Pharmaceuticals Ltd traded at A$7.52, Healius Ltd at A$0.50 and Avita Medical Inc at A$4.55, according to the session data provided.

Q: Are these closing prices?

A: No. They are session figures from the trading day on 6 November 2026.

Q: Is the session move linked to the company releases?

A: No. Each release is dated on a different day, and this article does not link any session move to a release.

Q: How did the health care index move?

A: The S&P/ASX 200 Health Care Index eased 0.20% to 35,258.30 during the session.

Q: Does this article give advice?

A: No. It reports session data and the company disclosures only.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.